X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES DIVIS LABORATORIES VENUS REMEDIES/
DIVIS LABORATORIES
 
P/E (TTM) x -7.6 32.8 - View Chart
P/BV x 0.1 5.3 2.2% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 VENUS REMEDIES   DIVIS LABORATORIES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
DIVIS LABORATORIES
Mar-17
VENUS REMEDIES/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1431,222 11.7%   
Low Rs65784 8.3%   
Sales per share (Unadj.) Rs324.2153.1 211.7%  
Earnings per share (Unadj.) Rs6.439.9 16.0%  
Cash flow per share (Unadj.) Rs40.644.6 91.0%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs366.0201.8 181.3%  
Shares outstanding (eoy) m12.34265.47 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.36.6 4.9%   
Avg P/E ratio x16.225.1 64.6%  
P/CF ratio (eoy) x2.622.5 11.4%  
Price / Book Value ratio x0.35.0 5.7%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m1,282266,266 0.5%   
No. of employees `0000.99.7 9.3%   
Total wages/salary Rs m2514,687 5.4%   
Avg. sales/employee Rs Th4,430.14,175.0 106.1%   
Avg. wages/employee Rs Th278.0481.5 57.7%   
Avg. net profit/employee Rs Th87.61,089.3 8.0%   
INCOME DATA
Net Sales Rs m4,00040,643 9.8%  
Other income Rs m23749 3.0%   
Total revenues Rs m4,02341,392 9.7%   
Gross profit Rs m78514,460 5.4%  
Depreciation Rs m4221,233 34.2%   
Interest Rs m34423 1,520.8%   
Profit before tax Rs m4213,953 0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-373,349 -1.1%   
Profit after tax Rs m7910,604 0.7%  
Gross profit margin %19.635.6 55.1%  
Effective tax rate %-87.924.0 -366.2%   
Net profit margin %2.026.1 7.6%  
BALANCE SHEET DATA
Current assets Rs m2,60640,105 6.5%   
Current liabilities Rs m1,9806,595 30.0%   
Net working cap to sales %15.682.5 19.0%  
Current ratio x1.36.1 21.6%  
Inventory Days Days128119 108.2%  
Debtors Days Days4381 53.5%  
Net fixed assets Rs m5,35319,995 26.8%   
Share capital Rs m123531 23.2%   
"Free" reserves Rs m4,39353,043 8.3%   
Net worth Rs m4,51653,574 8.4%   
Long term debt Rs m1,6180-   
Total assets Rs m8,29161,585 13.5%  
Interest coverage x1.1618.4 0.2%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.7 73.1%   
Return on assets %5.117.3 29.6%  
Return on equity %1.819.8 8.8%  
Return on capital %6.326.1 24.1%  
Exports to sales %00-   
Imports to sales %18.425.2 72.9%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m73610,259 7.2%   
Fx inflow Rs m035,384 0.0%   
Fx outflow Rs m73610,399 7.1%   
Net fx Rs m-73624,985 -2.9%   
CASH FLOW
From Operations Rs m99711,493 8.7%  
From Investments Rs m-461-11,372 4.1%  
From Financial Activity Rs m-571-93 613.3%  
Net Cashflow Rs m-3528 -123.6%  

Share Holding

Indian Promoters % 32.9 52.0 63.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.8 1.5%  
FIIs % 0.6 19.0 3.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.2 386.0%  
Shareholders   20,121 31,796 63.3%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 200 Points; Energy Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day in green.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jul 17, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - FRESENIUS KABI ONCO. COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS